Wolfe Research Starts Teva Pharma (TEVA) at Peerperform

Wolfe Research analyst Akash Tewari initiates coverage on Teva Pharma (NYSE: TEVA) with a Peerperform rating and a price target of $9.00.

The analyst comments "TEVA’s stock has lost ~47% YTD which marks material underperformance when compared to the DRG and S&P-500, which have gained ~2% and ~20%, respectively, over the same time period."

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $7.83 yesterday.

You May Also Be Interested In

• BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities
• BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy